Evidence map›Paper›PMID 36746754›Full record

SynthesisHuman vaccines & immunotherapeutics2023

Immunogenicity and safety of reduced-antigen tetanus, diphtheria and acellular pertussis vaccination in adults treated for obstructive airway diseases.

Peter Van den Steen, Brigitte Cheuvart, Quentin Deraedt, Laura Valdes Verelst, Dasha Shamarina

Open access · goldAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Human vaccines & immunotherapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Peter Van den SteenGSK, Wavre, Belgium.ORCID 0000-0001-7931-1781
Brigitte CheuvartGSK, Wavre, Belgium.ORCID 0000-0001-7156-0062
Quentin DeraedtGSK, Wavre, Belgium.ORCID 0000-0001-9226-2777
Laura Valdes VerelstGSK, Wavre, Belgium.ORCID 0000-0003-1929-8233
Dasha ShamarinaGSK, Wavre, Belgium.ORCID 0000-0002-4622-4224
GlaxoSmithKline (Belgium) · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with obstructive airway diseases (OAD), like chronic obstructive pulmonary disease (COPD) and asthma, may be at increased risk of pertussis infection. Pertussis may also trigger COPD and asthma exacerbations. Vaccination against pertussis could help protect OAD patients from the additional burden of pertussis, but there may be hesitancy related to vaccine safety and immunogenicity in such patients. We performed a meta-analysis on 5 clinical trials in adults receiving reduced-antigen tetanus-diphtheria-acellular pertussis vaccine (Tdap,

Indexed as

AsthmaDiphtheriaDiphtheria-Tetanus-acellular Pertussis VaccinesPulmonary Disease, Chronic ObstructiveTetanusWhooping CoughAdultAntibodies, BacterialBacterial VaccinesHumansImmunization, SecondaryVaccinationAntibodies, BacterialBacterial VaccinesDiphtheria-Tetanus-acellular Pertussis VaccinesadultsasthmaCOPDdTapimmunogenicityobstructive airway diseasespertussissafetyTdapvaccination

Identifiers

PMID36746754
PMCPMC9980557
OpenAlexW4319299061

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.